RBC Capital Initiates Coverage On Attovia Therapeutics with Outperform Rating, Announces Price Target of $45
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
RBC Capital analyst Brian Abrahams initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $45.
RBC Capital analyst Brian Abrahams initiates coverage on Attovia Therapeutics (NASDAQ:ATTO) with a Outperform rating and announces Price Target of $45.